CTGF, companied with YAP and CYR61 can be highly expressed in tamoxifen resistant breast cancer, leading to poor prognosis in patients [56], suggesting that CTGF is an important component of YAP in promoting tumor development. Here, CCN2 is linked to breast cancer.